Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Dianthus Therapeutics (DNTH) Operating Margin (2022 - 2025)

Dianthus Therapeutics has reported Operating Margin over the past 4 years, most recently at 10173.74% for Q3 2025.

  • Quarterly results put Operating Margin at 10173.74% for Q3 2025, down 879713.0% from a year ago — trailing twelve months through Sep 2025 was 4558.41% (down 301343.0% YoY), and the annual figure for FY2024 was 1633.74%, up 7093.0%.
  • Operating Margin for Q3 2025 was 10173.74% at Dianthus Therapeutics, up from 18096.89% in the prior quarter.
  • Over the last five years, Operating Margin for DNTH hit a ceiling of 2584.8% in Q4 2022 and a floor of 18096.89% in Q2 2025.
  • Median Operating Margin over the past 4 years was 1705.52% (2023), compared with a mean of 3314.07%.
  • Biggest five-year swings in Operating Margin: skyrocketed 42807bps in 2024 and later tumbled -1690505bps in 2025.
  • Dianthus Therapeutics' Operating Margin stood at 2584.8% in 2022, then plummeted by -210bps to 2835.01% in 2023, then increased by 15bps to 2406.94% in 2024, then tumbled by -323bps to 10173.74% in 2025.
  • The last three reported values for Operating Margin were 10173.74% (Q3 2025), 18096.89% (Q2 2025), and 2852.71% (Q1 2025) per Business Quant data.